877-88-3

Usage

Uses

Used in Organic Synthesis:
3,5-Dimethoxybenzyl bromide is used as a key intermediate in the synthesis of various organic compounds, such as 3,4,3′,5′-tetramethoxystilbene, 3,5-dimethoxyphenylacetic acid, and 1-(3,5-dimethoxyphenyl)-4-pentene. Its presence in these molecules allows for the formation of complex structures and functional groups that are essential in various applications.
Used in Pharmaceutical Synthesis:
3,5-Dimethoxybenzyl bromide is used as a starting material in the multi-step synthesis of resveratrol and 3,5-dimethoxyhomophthalic acid. Resveratrol is a natural polyphenol with antioxidant, anti-inflammatory, and anti-cancer properties, while 3,5-dimethoxyhomophthalic acid is a key intermediate in the synthesis of various pharmaceuticals.
Used in Dimethoxybenzene Alkyl Addition:
3,5-Dimethoxybenzyl bromide is used in the alkyl addition reactions of dimethoxybenzene. This process allows for the formation of new compounds with different functional groups and properties, which can be further utilized in various chemical and pharmaceutical applications.

InChI:InChI=1/C9H11BrO2/c1-11-8-3-7(6-10)4-9(5-8)12-2/h3-5H,6H2,1-2H3

Synthetic route

3,5-dimethoxybenzyl alcohol (705-76-0) → 3,5-dimethoxybenzyl bromide (877-88-3)

Conditions	Yield
With phosphorus tribromide In benzene at 20℃;	100%
With phosphorus tribromide In 1,4-dioxane at 40℃; for 1h; Inert atmosphere;	99%
Stage #1: 3,5-dimethoxybenzyl alcohol With triphenylphosphine In dichloromethane at 20℃; for 0.166667h; Appel reaction; Stage #2: With carbon tetrabromide In dichloromethane at -78 - -50℃; Appel reaction;	98%

1,3-Dimethoxy-5-(4-methoxy-benzyloxymethyl)-benzene → 3,5-dimethoxybenzyl bromide (877-88-3)

Conditions	Yield
With carbon tetrabromide; triphenylphosphine In dichloromethane at 0 - 30℃; for 1.5h;	48%

ethyl 3,5-dimethoxybenzoate (17275-82-0) → 3,5-dimethoxybenzyl bromide (877-88-3)

Conditions	Yield
(i) LiAlH4, (ii) PBr3; Multistep reaction;

3,5-dimethoxybenzaldehdye (7311-34-4) → 3,5-dimethoxybenzyl bromide (877-88-3)

Conditions	Yield
With phosphorus tribromide In dichloromethane for 1h; Ambient temperature; Yield given;
Multi-step reaction with 2 steps 1: 93 percent / NaBH4 / methanol / 0 °C 2: 89 percent / PBr3 / CH2Cl2 / 12 h / 0 °C View Scheme
Multi-step reaction with 2 steps 1: 98 percent / NaBH4 / ethanol 2: 88 percent / PBr3, pyridine / diethyl ether / 1 h View Scheme

(3,5-dimethoxyphenyl)methyl methanesulfonate (192997-46-9) → 3,5-dimethoxybenzyl bromide (877-88-3)

Conditions	Yield
With lithium bromide In tetrahydrofuran for 15h; Ambient temperature; Yield given;

methyl 3,5-dimethoxybenzoate (2150-37-0) → 3,5-dimethoxybenzyl bromide (877-88-3)

Conditions	Yield
(i) LiAlH4, (ii) PBr3; Multistep reaction;
Multi-step reaction with 2 steps 1: 92 percent / LiAlH4 / diethyl ether 2: 94 percent / PBr3 / CH2Cl2 View Scheme
Multi-step reaction with 2 steps 1: LiAlH4 / diethyl ether 2: HBr / benzene View Scheme

3,5-dimethoxybenzoic acid (1132-21-4) → 3,5-dimethoxybenzyl bromide (877-88-3)

Conditions	Yield
Multi-step reaction with 2 steps 1.1: LiAlH4 / tetrahydrofuran / 3 h / 20 °C 1.2: 97 percent / Na/K tartrate / tetrahydrofuran / 1 h / 20 °C 2.1: 86 percent / PBr3 / CH2Cl2 / 1 h / 20 °C View Scheme
Multi-step reaction with 4 steps 1: SOCl2 2: 92 percent / LiAlH4 / diethyl ether 3: 94 percent / PBr3 / CH2Cl2 View Scheme
Multi-step reaction with 2 steps 1: BH3 / tetrahydrofuran / 2 h / Heating 2: CBr4; tri-n-octylphosphine / diethyl ether / 2 h / 20 °C View Scheme

3,5-Dihydroxybenzoic acid (99-10-5) → 3,5-dimethoxybenzyl bromide (877-88-3)

Conditions	Yield
Multi-step reaction with 5 steps 1: NaOH 2: SOCl2 3: 92 percent / LiAlH4 / diethyl ether 4: 94 percent / PBr3 / CH2Cl2 View Scheme
Multi-step reaction with 3 steps 1.1: potassium carbonate / acetone / 4 h / Reflux 2.1: lithium aluminium tetrahydride / tetrahydrofuran / 2.17 h / 0 - 20 °C 3.1: triphenylphosphine / dichloromethane / 0.17 h / 20 °C 3.2: -78 - -50 °C View Scheme
Multi-step reaction with 3 steps 1: potassium carbonate / acetone / 4.5 h / 60 °C 2: sodium tetrahydroborate / methanol; tetrahydrofuran / 2.5 h / 70 °C 3: phosphorus tribromide / dichloromethane / 2 h / 20 °C View Scheme

3,5-dimethoxybenzoyl chloride (17213-57-9) → 3,5-dimethoxybenzyl bromide (877-88-3)

Conditions	Yield
Multi-step reaction with 3 steps 1: 92 percent / LiAlH4 / diethyl ether 2: 94 percent / PBr3 / CH2Cl2 View Scheme

3,5-Dihydroxybenzoic acid (99-10-5) + dimethyl sulfate (77-78-1) → 3,5-dimethoxybenzyl bromide (877-88-3)

Conditions	Yield
Stage #1: 3,5-Dihydroxybenzoic acid; dimethyl sulfate With potassium carbonate In acetone for 4h; Reflux; Stage #2: With lithium aluminium tetrahydride In tetrahydrofuran at 0 - 20℃; Stage #3: With phosphorus tribromide In dichloromethane at 0 - 20℃;

1,3-dimethoxy-5-methylbenzene (4179-19-5) → 3,5-dimethoxybenzyl bromide (877-88-3)

Conditions	Yield
With N-Bromosuccinimide In acetonitrile at 25℃; for 1h; Inert atmosphere;	1.05 g

1-carbomethoxy-3,5-dihydroxybenzene (2150-44-9) → 3,5-dimethoxybenzyl bromide (877-88-3)

Conditions	Yield
Multi-step reaction with 3 steps 1: potassium carbonate / acetone / 48 h / 50 °C 2: lithium aluminium tetrahydride / tetrahydrofuran / 3 h / 0 - 20 °C 3: phosphorus tribromide / tetrahydrofuran / -10 °C View Scheme

3,5-dimethoxybenzyl bromide (877-88-3) + triphenylphosphine (603-35-0) → (3,5-dimethoxybenzyl)triphenylphosphonium bromide (24131-30-4)

Conditions	Yield
In acetonitrile for 4.5h; Reflux;	100%
In benzene for 2h; reflux;	99%
In toluene for 24h; Inert atmosphere; Reflux;	99%

3,5-dimethoxybenzyl bromide (877-88-3) + triethyl phosphite (122-52-1) → diethyl 3,5-dimethoxybenzylphosphonate (108957-75-1)

Conditions	Yield
Esterification; Arbusov reaction;	100%
at 100℃;	98%
In 5,5-dimethyl-1,3-cyclohexadiene for 10h; Michaelis-Arbuzov reaction; Reflux; Inert atmosphere;	96%

3,5-dimethoxybenzyl bromide (877-88-3) + sodium cyanide (143-33-9) → 3,5-dimethoxyphenylacetonitrile (13388-75-5)

Conditions	Yield
In dimethyl sulfoxide at 35 - 40℃; for 1.5h;	100%
In N,N-dimethyl-formamide for 1h;	83%

3,5-dimethoxybenzyl bromide (877-88-3) + vinyl magnesium bromide (1826-67-1) → Methoxyeugenol (64118-89-4)

Conditions	Yield
Stage #1: vinyl magnesium bromide With copper(l) iodide In tetrahydrofuran at -50℃; Stage #2: 3,5-dimethoxybenzyl bromide In tetrahydrofuran at -30 - 20℃;	100%

3,5-dimethoxybenzyl bromide (877-88-3) + methyl 2-cyanoacetate (105-34-0) → cyano-di(3,5-dimethoxy-benzyl)acetic acid methyl ester (1202779-02-9)

Conditions	Yield
Stage #1: methyl 2-cyanoacetate With sodium methylate In methanol at 20℃; Stage #2: 3,5-dimethoxybenzyl bromide In methanol Reflux;	100%

1-(3-methoxyphenethyl)-3,5-bis(3-methoxyphenyl)-1,2,3,6-tetrahydropyridine (1006606-32-1) + 3,5-dimethoxybenzyl bromide (877-88-3) → Br(1-)*C37H42NO5(1+) (1187632-62-7)

Conditions	Yield
In acetone at 60℃; Inert atmosphere;	100%

3,5-dimethoxybenzyl bromide (877-88-3) + trimethylsilylacetylene (1066-54-2) → (3-(3,5-dimethoxyphenyl)prop-1-ynyl)trimethylsilane (1394837-78-5)

Conditions	Yield
Stage #1: trimethylsilylacetylene With ethylmagnesium bromide In tetrahydrofuran; diethyl ether at 0 - 20℃; for 0.5h; Stage #2: With copper(I) bromide In tetrahydrofuran; diethyl ether at 20℃; for 0.25h; Stage #3: 3,5-dimethoxybenzyl bromide In tetrahydrofuran; diethyl ether at 66℃;	100%

5-hydroxy-6-methoxy-2-methylisoquinolin-1(2H)-one (1043429-55-5) + 3,5-dimethoxybenzyl bromide (877-88-3) → 5-(3,5-dimethoxybenzyloxy)-6-methoxy-2-methylisoquinolin-1(2H)-one (1043429-21-5)

Conditions	Yield
With potassium carbonate In N,N-dimethyl-formamide at 20℃;	100%

3,5-dimethoxybenzyl bromide (877-88-3) + dimethyl (prop-2-yn-1-yl)malonate (95124-07-5) → dimethyl 2-(3,5-dimethoxybenzyl)-2-(prop-2-yn-1-yl)malonate

Conditions	Yield
Stage #1: dimethyl (prop-2-yn-1-yl)malonate With sodium hydride In tetrahydrofuran; mineral oil at 0 - 20℃; Inert atmosphere; Stage #2: 3,5-dimethoxybenzyl bromide In tetrahydrofuran; mineral oil at 0 - 20℃; for 20h; Inert atmosphere;	100%

5-(hydroxymethyl)benzene-1,3-diol (29654-55-5) + 3,5-dimethoxybenzyl bromide (877-88-3) → 3,5-bis(3,5-dimethoxybenzyloxy)benzyl alcohol (176650-92-3)

Conditions	Yield
With dibenzo-18-crown-6; potassium carbonate In acetone for 36h; Inert atmosphere; Reflux;	99%

3,5-dihydroxybenzaldehyde (26153-38-8) + 3,5-dimethoxybenzyl bromide (877-88-3) → 3,5-bis-(3,5-dimethoxy-benzyloxy)-benzaldehyde

Conditions	Yield
With potassium carbonate In N,N-dimethyl-formamide at 50℃; for 1.5h;	99%
With potassium carbonate In N,N-dimethyl-formamide Inert atmosphere; Schlenk technique;	77%

triethyl phosphate (78-40-0) + 3,5-dimethoxybenzyl bromide (877-88-3) → diethyl 3,5-dimethoxybenzylphosphonate (108957-75-1)

Conditions	Yield
at 160℃; for 4h;	99%
at 120℃; for 10h;	95%
at 160℃; for 4h;	95%

3,5-dimethoxybenzyl bromide (877-88-3) + quinindine (56-54-2, 130-95-0, 572-59-8, 572-60-1, 42151-59-7, 47342-58-5, 72402-50-7, 72402-51-8, 72402-52-9, 72402-53-0, 101143-86-6, 101143-87-7, 101143-88-8, 146925-10-2) → C29H35N2O4(1+)*Br(1-)

Conditions	Yield
In toluene at 80℃; for 2h;	99%

3,5-dimethoxybenzyl bromide (877-88-3) + diothiothreitol (3483-12-3, 6892-68-8, 7634-42-6, 16096-97-2, 27565-41-9, 35454-97-8) → 1,4-bis-(3,5-dimethoxy-benzylsulfanyl)-butane-2,3-diol

Conditions	Yield
Stage #1: diothiothreitol With sodium hydroxide In ethanol Stage #2: 3,5-dimethoxybenzyl bromide In tetrahydrofuran; ethanol at 20℃; for 5h;	98%

N,N,N,N,-tetramethylethylenediamine (110-18-9) + 3,5-dimethoxybenzyl bromide (877-88-3) → N,N'-ethane-1,2-diyl N,N'-bis(3,5-dimethoxybenzyloxy) N,N,N',N'-tetramethylammonium dibromide

Conditions	Yield
In N,N-dimethyl-formamide at 70℃; Inert atmosphere;	98%
In N,N-dimethyl-formamide at 70℃; for 15h; Inert atmosphere;	98%

3,5-dimethoxybenzyl bromide (877-88-3) + phenylacetylene (536-74-3) → 1-(3,5-dimethoxybenzyl)-4-phenyl-1H-1,2,3-triazole

Conditions	Yield
With sodium azide; CuNPs/C In water at 70℃; for 4h;	98%
With sodium azide; copper nanoparticles on activated carbon In water at 70℃; for 4h; regioselective reaction;	98%
With sodium azide at 50℃; for 48h;	89%
With sodium azide In water at 80℃; for 6h;	86%

2,2,4,4-tetramethylpentane-1,3-diol (33950-45-7) + 3,5-dimethoxybenzyl bromide (877-88-3) → 1-(3,5-dimethoxybenzyloxy)-2,2,4,4-tetramethylpentan-3-ol (1313999-66-4)

Conditions	Yield
Stage #1: 2,2,4,4-tetramethylpentane-1,3-diol With sodium hydride In tetrahydrofuran; N,N-dimethyl-formamide; mineral oil at 0℃; for 0.75h; Inert atmosphere; Stage #2: 3,5-dimethoxybenzyl bromide In tetrahydrofuran; N,N-dimethyl-formamide; mineral oil at 20℃; for 5h;	97%

3,5-dimethoxybenzyl bromide (877-88-3) + N-(diphenylmethylene)glycine tert-butyl ester (81477-94-3) → (S)-tert-butyl N-(diphenylmethylene)-(3,5-dimethoxyphenyl)alaninate

Conditions	Yield
With C37H37N2O(1+)*Br(1-); potassium hydroxide In chloroform; water; toluene at -40℃; for 72h; enantioselective reaction;	97%

3,5-dimethoxybenzyl bromide (877-88-3) + C11H13F3O3SZn → 1-(4-tert-butylbenzyl)-3,5-dimethoxybenzene

Conditions	Yield
With tetrakis(triphenylphosphine) palladium(0) In N,N-dimethyl acetamide at 60℃; for 24h; Inert atmosphere; Schlenk technique;	97%

3,5-dimethoxybenzyl bromide (877-88-3) → (E)-3,3',5,5'-tetramethoxystilbene (80715-09-9, 125910-10-3, 125910-07-8)

Conditions	Yield
With Benzyl phenyl selenoxide; potassium hexamethylsilazane In toluene at 25℃; for 4h; Inert atmosphere;	96%
With lithium diisopropyl amide In tetrahydrofuran; hexane a.) -50 deg C, 30 min, b.) RT, 1.5 h;	69%
Multi-step reaction with 2 steps 1: tetrabutylammonium iodide / 110 - 130 °C 2: sodium hydride / dimethylformamide / 20 °C View Scheme

3,5-dimethoxybenzyl bromide (877-88-3) + phenyltriisopropoxytitanium(IV) (16635-23-7) → (3,5-dimethoxyphenyl)phenylmethane (52692-17-8)

Conditions	Yield
With palladium diacetate; Tri(p-tolyl)phosphine In toluene at 60℃; for 2h; Inert atmosphere;	96%

4,4'-bipyridine (553-26-4) + 3,5-dimethoxybenzyl bromide (877-88-3) → C28H30N2O4(2+)*2Br(1-)

Conditions	Yield
In N,N-dimethyl-formamide at 55℃; for 96h;	96%

3,5-dimethoxybenzyl bromide (877-88-3) + C54H68N2O11 → C72H88N2O15

Conditions	Yield
With potassium carbonate In chloroform for 24h; Reflux;	96%

3,5-dimethoxybenzyl bromide (877-88-3) + malononitrile (109-77-3) → C21H22N2O4

Conditions	Yield
With 1,8-diazabicyclo[5.4.0]undec-7-ene In N,N-dimethyl-formamide at 80℃; for 2h; Green chemistry;	96%

silver(I) trifluoromethoxide (1006904-72-8) + 3,5-dimethoxybenzyl bromide (877-88-3) → 1,3-dimethoxy-5-((trifluoromethoxy)methyl)benzene

Conditions	Yield
Stage #1: 3,5-dimethoxybenzyl bromide In acetonitrile at -30℃; for 0.0833333h; Glovebox; Stage #2: silver(I) trifluoromethoxide In acetonitrile at 20℃; for 12h; Glovebox;	95.8%

3,5-dimethoxybenzyl bromide (877-88-3) → 3,5,3',5'-tetramethoxy-bibenzyl (22976-41-6)

Conditions	Yield
With iodine; magnesium In diethyl ether for 2.5h; Heating;	95%
With (Cp2TiCl)2; water In tetrahydrofuran for 3h; Inert atmosphere;	90%
With sodium In diethyl ether for 20h; Heating;	68%

3,5-dimethoxybenzyl bromide (877-88-3) → 2-bromo-1-(bromomethyl)-3,5-dimethoxybenzene (34132-25-7)

Conditions	Yield
With N-Bromosuccinimide In dichloromethane at 0℃; for 1h;	95%
With N-Bromosuccinimide In dichloromethane at 0℃; for 1h;	95%
With N-Bromosuccinimide In dichloromethane at 20℃; for 1h;	87%
With N-Bromosuccinimide In dichloromethane at 20℃; for 4h;	86%
With N-Bromosuccinimide In dichloromethane at 0℃; for 1h; Inert atmosphere;

2-Methylcyclopentanone (1120-72-5) + 3,5-dimethoxybenzyl bromide (877-88-3) → 2-(3,5-dimethoxybenzyl)-2-methylcyclopentanone

Conditions	Yield
Stage #1: 2-Methylcyclopentanone With n-butyllithium In tetrahydrofuran; hexane at -78 - 20℃; for 6.5h; Stage #2: 3,5-dimethoxybenzyl bromide In tetrahydrofuran; hexane for 96h; Heating; Further stages.;	95%

3,5-dimethoxybenzyl bromide (877-88-3) + sodium benzenesulfonate (873-55-2) → 3,5-dimethoxybenzyl phenyl sulfone

Conditions	Yield
In N,N-dimethyl-formamide at 20℃; for 2h;	95%

Upstream product

• 7311-34-4 3,5-dimethoxybenzaldehdye 
• 99-10-5 3,5-Dihydroxybenzoic acid 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 
• 4179-19-5 1,3-dimethoxy-5-methylbenzene 
• 77-78-1 dimethyl sulfate 
• 17213-57-9 3,5-dimethoxybenzoyl chloride 
• 1132-21-4 3,5-dimethoxybenzoic acid 
• 2150-37-0 methyl 3,5-dimethoxybenzoate 
• 192997-46-9 (3,5-dimethoxyphenyl)methyl methanesulfonate 
• 705-76-0 3,5-dimethoxybenzyl alcohol 
• 17275-82-0 ethyl 3,5-dimethoxybenzoate 

Downstream Products

• 41497-39-6 1-(3,5-Dimethoxyphenyl)-2-methylsulfonyl-pentan-3-on 
• 41497-40-9 2-(3,5-Dimethoxybenzyl)-1-(3,5-dimethoxyphenyl)-2-methylsulfonyl-pentan-3-on 
• 41497-41-0 1-(3,5-Dimethoxyphenyl)-2-methylsulfonyl-hexan-3-on 
• 22976-41-6 3,5,3',5'-tetramethoxy-bibenzyl 
• 7311-34-4 3,5-dimethoxybenzaldehdye 
• 4179-19-5 1,3-dimethoxy-5-methylbenzene 
• 125846-91-5 trans-2-<(3,5-dimethoxyphenyl)methyl>-3--cyclohexan-1-one 
• 74149-58-9 2-(3,5-dimethoxyphenylmethyl)-2-s-butyl-1,3-dithian 
• 125877-13-6 trans-2-<(3,5-dimethoxyphenyl)methyl>-3--cyclopentan-1-one 
• 75887-69-3 1-<3,5-Dimethoxybenzyl>-aethan-1,1,2-tricarbonsaeure-triaethylester 
• 54879-37-7 N-(3,5-Dimethoxy-benzyl)-N-(2,2-dimethoxy-ethyl)-4-methyl-benzenesulfonamide 
• 96215-83-7 1,3-dimethoxyphenol-5-nonadecylbenzene 
• 82055-03-6 (1S,3aS,4S,7aS)-1-tert-Butoxy-4-<(1S)-2-(3,5-dimethoxyphenyl)-1-(phenylsulfonyl)ethyl>-5,5-(ethylendioxy)-2,3,3a,4,5,6,7,7a-octahydro-7a-methyl-1H-inden 
• 82079-97-8 (1S,3aS,4S,7aS)-1-tert-Butoxy-4-<(1R)-2-(3,5-dimethoxyphenyl)-1-(phenylsulfonyl)ethyl>-5,5-(ethylendioxy)-2,3,3a,4,5,6,7,7a-octahydro-7a-methyl-1H-inden 

Relevant academic research and scientific papers

Studies toward the synthesis of caramboxin analogues

Intrigued by the recent discovery of caramboxin by Brazilian researchers, we present the results from our studies toward the racemic synthesis of caramboxin analogs through the ortho-carboxylation of 3,5-dimethoxy benzyl derivatives. Three different approaches were tested, and the route involving a Vilsmeier-Haack formylation followed by a Lindgren oxidation provide a potential intermediate for the synthesis of several caramboxin analogs.

Preparation method of resveratrol

The invention belongs to the technical field of preparation of medicine key intermediates, and particularly relates to a preparation method of resveratrol. The synthesis and preparation method of theresveratrol comprises the following steps: a, taking 3, 5-dimethoxybenzyl alcohol and phosphorus tribromide as raw materials, and synthesizing 3, 5-dimethoxybenzyl bromide (a compound A); b, taking the compound A, triethyl phosphite and tetrabutylammonium bromide as raw materials, and synthesizing to obtain 3, 5-dimethoxy benzyl diethyl phosphate (a compound B); c, taking the compound B, dimethyldiamide, sodium hydride and anisaldehyde as raw materials, and carrying out a reaction to synthesize to obtain (E) 3, 4 ', 5-trimethoxystilbene (compound C); and d, using the compound C and pyridine hydrochloride as raw materials, carrying out a reaction to synthesize 3, 4, 5-trihydroxy-1, 2-stilbene, namely the resveratrol. The method has the characteristics of cheap and easily available raw materials, mild reaction conditions, simple operation, high yield and low cost, and is beneficial to industrial production.

Discovery of boron-containing compounds as Aβ aggregation inhibitors and antioxidants for the treatment of Alzheimer's disease

A novel series of boron-containing compounds were designed, synthesized and evaluated as multi-target-directed ligands against Alzheimer's disease. The biological activity results demonstrated that these compounds possessed a significant ability to inhibit self-induced Aβ aggregation (20.5-82.8%, 20 μM) and to act as potential antioxidants (oxygen radical absorbance capacity assay using fluorescein (ORAC-FL) values of 2.70-5.87). In particular, compound 17h is a potential lead compound for AD therapy (IC50 = 3.41 μM for self-induced Aβ aggregation; ORAC-FL value = 4.55). Compound 17h also functions as a metal chelator. These results indicated that boron-containing compounds could be new structural scaffolds for the treatment of AD.

Cancerous Cell Growth Inhibiting Compounds

The present invention provides a compound of Formula I, II or III or a salt or prodrug or derivative thereof that is useful for skin-whitening by inhibiting melanin formation and removing existing melanin and the inhibition of melanoma growth and/or the removal of existing melanoma cells.

Design and synthesis of imidazo[2,1-b]thiazole linked triazole conjugates: Microtubule-destabilizing agents

A series of imidazo[2,1-b]thiazole linked triazole conjugates were synthesized by using Huisgen 1,3-dipolar cyclo-addition reaction (click chemistry approach) and evaluated for their antiproliferative activity against some human cancer cell lines like, HeLa (cervical), DU-145 (prostate), A549 (lung), MCF-7 (breast) and HepG2 (liver). Among them, Conjugates 4g and 4h demonstrated a significant antiproliferative effect against human lung cancer cells (A549) with IC50values of 0.92 and 0.78 μM respectively. Flow cytometric analysis revealed that these conjugates induced cell cycle arrest in G2/M phase in A549 lung cancer cells. The tubulin polymerization assay and immunofluorescence analysis showed that these conjugates effectively inhibit microtubule assembly in cell free and cell based (A549) experiment respectively. Moreover, the apoptosis inducing properties were evaluated by Hoechst staining, mitochondrial membrane potential and Annexin V-FITC assay. Further, western blot analysis was performed for proapoptotic protein Bax and antiapoptotic protein Bcl-2 and the results demonstrated that there was up regulation of Bax and down regulation of Bcl-2 suggesting that these compounds induced apoptosis in human lung cancer cells, A549.

Design and synthesis of 1,2,3-triazolo linked benzo[d]imidazo[2,1-b]thiazole conjugates as tubulin polymerization inhibitors

1,2,3-Triazolo linked benzo[d]imidazo[2,1-b]thiazole conjugates (5a–v) were designed, synthesized and evaluated for their cytotoxic potency against some human cancer cell lines like DU-145 (prostate), HeLa (cervical), MCF-7 (breast) HepG2 (liver) and A549 (lung). Preliminary results revealed that some of these conjugates like 5f and 5k exhibited significant antiproliferative effect against human breast cancer cells (MCF-7) with IC50 values of 0.60 and 0.78?μM respectively. Flow cytometric analysis of the cell cycle demonstrated an increase in the percentage of cells in the G2/M phase which was further authenticated by elevation of cyclin B1 protein levels. Immunocytochemistry revealed loss of intact microtubule structure in cells treated with 5f and 5k, and western blot analysis revealed that these conjugates accumulated more tubulin in the soluble fraction. Moreover, the conjugates caused apoptosis of the cells that was confirmed by mitochondrial membrane potential and Annexin V-FITC assay. Molecular docking studies indicated that these conjugates occupy the colchicine binding site of the tubulin protein.

Synthesis and bioactivity evaluation of 2,3-diaryl acrylonitrile derivatives as potential anticancer agents

Thirty novel derivatives of 2,3-diaryl acrylonitrile were synthesized and evaluated for biological activity. Preliminary investigations of antitumor activity in vitro showed that most of the synthesized compounds have significant antiproliferative effects

Dehydrogenative Formation of Resorcinol Derivatives Using Pd/C-Ethylene Catalytic System

The conversion of substituted 1,3-cyclohexanediones to the alkyl ethers of resorcinol using a Pd/C-ethylene system is reported. In these reactions, ethylene works as a hydrogen acceptor. The efficient synthesis of resveratrol was achieved using this protocol as a key step. In addition, the direct formation of substituted resorcinols was carried out by adding K2CO3 into the reaction media.

FGFR4 INHIBITORS

Methods, compounds, pharmaceutical compositions, and methods of preparing medicaments for treating hepatocellular carcinoma having an altered FGFR4 and/or FGF19 status.

Synthesis and biological evaluation of novel resveratrol-oxadiazole hybrid heterocycles as potential antiproliferative agents

A novel class of resveratrol-oxadiazole hybrid compounds was synthesized to screen for their in vitro antiproliferative activity against three human cancer cell lines. All the compounds showed superior antiproliferative activity than the reference compound resveratrol. The most promising active compounds in this series were 1g, 2g, 1c, 2c, 2i and 1a (GI50 0.1 μM), endowed with excellent antiproliferative activity. Thus, we believe that resveratrol-oxadiazole hybrid compounds may possibly be used as a good leads for the development of new antiproliferative agents. Structures of newly synthesized compounds were confirmed by NMR and IR spectral data.